Pirtobrutinib and Venetoclax Combination Overcomes Resistance to Targeted and Chimeric Antigen Receptor T-Cell Therapy in Aggressive Mantle Cell Lymphoma

Authors

Yang Liu
Fangfang Yan
Vivian Changying Jiang
Yijing Li
Yuxuan Che
Joseph McIntosh
Alexa Jordan
Ian Hou
Lei Nie
Jingling Jin
Wei Wang
Heng-Huan Lee
Yixin Yao
Michael Wang

Publication Date

5-1-2023

Journal

Haematologica

DOI

10.3324/haematol.2022.282031

PMID

36475521

PMCID

PMC10153528

PubMedCentral® Posted Date

12-7-2022

PubMedCentral® Full Text Version

Post-print

Keywords

Adult, Humans, Lymphoma, Mantle-Cell, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Cell- and Tissue-Based Therapy

Published Open-Access

yes

Recommended Citation

Liu, Yang; Yan, Fangfang; Jiang, Vivian Changying; et al., "Pirtobrutinib and Venetoclax Combination Overcomes Resistance to Targeted and Chimeric Antigen Receptor T-Cell Therapy in Aggressive Mantle Cell Lymphoma" (2023). Faculty, Staff and Student Publications. 4763.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4763